Track topics on Twitter Track topics that are important to you
This KOL Insight briefing focuses on KOLs views of Treatment strategies for pregnant RA patients.
Current views on suitable therapies to treat pregnant RA patients
Certolizumab use in pregnant RA patients
Other antiTNFs use in pregnant RA patients
IL6 inhibitors use in pregnant RA patients
Abatacept use in pregnant RA patients
JAK inhibitors use in pregnant RA patients
Majority of KOLs currently use antiTNFs for treating pregnant RA patients, with a marked preference for certolizumab
No consensus among KOLs on the use of IL6 inhibitors during pregnancy, although monotherapy use was not considered an advantage
Majority of KOLs were averse to prescribing JAK inhibitors during pregnancy, primarily due to the lack of any data in this setting.
The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs.
In total, we conducted interviews with 10 KOLs
5 Europebased 5 N. Americabased
Interviews performed during Apr 2018
KOL data is analyzed to produce
Charts summarizing KOL opinions
Chart callouts of key information details
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on Treatment strategies for pregnant RA patients
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of RA
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.NEXT ARTICLE
Obstetrics and gynaecology
Fertility Menopause Obstetrics & Gynaecology Osteoporosis Women's Health Obstetrics and gynaecology comprises the care of the pregnant woman, her unborn child and the management of diseases specific to women. Most consultant...